Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Add filters

Document Type
Year range
Pharmaceutical Technology Europe ; 35(1):17-18, 2023.
Article in English | ProQuest Central | ID: covidwho-20232972


Attracting investor attention In January 2022, the company was recognized as one of the top 25 BioTech start-ups (1). Since its conception, it has attracted USS86.9 million (€80.8 million) in series A and B funding from private equity investors, including Leonard Green and Partners, XAnge, AQUITI Gestion, BNP Paribas Developpement, and Bpifrance, as well as Bristol Myers Squibb, Aquitaine Science Transfer, and the European Commission (1). First-in-human trial expected in 2024 TreeFrog's lead programme targets Parkinson's disease via the generation of three-dimensional (3D) neurospheres which contain mature dopaminergic neurons. In 2022, TreeFrog awarded several Stem Cell SpaceShot grants to leading academic institutions including the University of Sheffield, UK;MCR Laboratory of Molecular Biology, 13 Dec 2022).

Pharmaceutical Technology Europe ; 35(5):16-17,30, 2023.
Article in English | ProQuest Central | ID: covidwho-20232971


Advances in tissue engineering, microfabrication, and biocompatible microfluidic chambers alongside the governmental (2) and regulatory (3) appetite to seek animal-free innovations in the drug development process has fuelled further interest and investment in this marketplace. According to market research, the global O°C market is forecast to be worth US$388 million (€354 million) by 2028 increasing from US$82 million (€75 million) in 2023, with a compound average growth of 36.4% from 2023 to 2028 (4). In March 2022, Lyon-based NETRI, attracted €8 million series A funding to help develop its novel high throughput (HT) compartmentalized microfluidic brain-on-a-chip and skin-on-a-chip technology for use by the pharma and cosmetic industry (15). Global Organ-onChip Market Size, Share, Trends, COVID-19 Impact and Growth Analysis ReportSegmented by Type (Heart-on-chip, Humanon-chip, Intestine-on-chip, Kidney-on-chip, Liver-on-chip and Lung-on-chip), Application and Region (North America, Europe, AsiaPacific, Latin America, Middle East and Africa)-Industry Forecast from 2023 to 2028.

Pharmaceutical Technology Europe ; 34(1):8-9, 2022.
Article in English | ProQuest Central | ID: covidwho-20232970


Conversely, in Italy DTx are classed as medical devices and must pass International Organization for Standardization (ISO) standards to ensure they are compliant with safety requirements. The new EU MDR should help to simplify the exchange of data on medical devices and improve data collection and post-market surveillance to reinforce end-user confidence in DTx solutions. In Germany, Ireland, and the Netherlands, DTx manufacturers have directly targeted self-insured employer health plans, whereas in France, Belgium, and the United Kingdom, a B2P reimbursement model has proven successful.

Pharmaceutical Technology Europe ; 34(12):8-9, 2022.
Article in English | ProQuest Central | ID: covidwho-20232969


On 1 March 2021, the EC published its roadmap to revise the general pharmaceutical legislations building on lessons learnt from the COVID-19 pandemic to ensure that the future regulatory framework is fit-for-purpose and crisis-resistant (3). Since the EC published its strategy roadmap, it has conducted a series of consultations and has proposed a series of amendments to: o ensure access to affordable medicines o foster innovation, including in areas of unmet medical need o improve security of supply o adapt to new scientific and technological developments o reduce red tape (8). The Regulatory Scrutiny Board (RSB), an independent body within the EC that undertakes impact assessments and evaluation fitness checks, has reviewed the proposal and drafted a number of negative opinions. According to EFPIA, the overall goal of the new regulations should be to reinforce expertise-driven assessment and enable a more agile centralized authorization framework by facilitating member states and removing unnecessary, burdensome interfaces between committees and the EC (Figure 2).